• Asghari V., Sanyal S., Buchwaldt S., Paterson A., Jovanovic V. and Van Tol H. H. (1995) Modulation of intracellular cyclic AMP levels by different human dopamine D4 receptor variants. J. Neurochem. 65, 11571165.
  • Bristow L. J., Collinson N., Cook G. P. et al. (1997) L-745,870, a subtype selective dopamine D4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioral tests. J. Pharmacol. Exp. Ther. 283, 12561263.
  • Claesson-Welsh L., Ronnstrand L. and Heldin C. H. (1987) Biosynthesis and intracellular transport of the receptor for platelet-derived growth factor. Proc. Natl Acad. Sci. USA 84, 87968800.
  • Daniel T. O., Milfay D. F., Escobedo J. and Williams L. T. (1987) Biosynthetic and glycosylation studies of cell surface platelet-derived growth factor receptors. J. Biol. Chem. 262, 97789784.
  • Glase S. A., Akunne H. C., Georgic L. M., Heffner T. G., MacKenzie R. G., Manley P. J., Pugsley T. A. and Wise L. D. (1997) Substituted [(4-phenylpiperazinyl)-methyl]benzamides: selective dopamine D4 agonists. J. Med. Chem. 40, 17711772.
  • Gu Z., Jiang Q., Fu A. K., Ip N. Y. and Yan Z. (2005) Regulation of NMDA receptors by neuregulin signaling in prefrontal cortex. J. Neurosci. 25, 49744984.
  • Heldin C. H., Ostman A. and Ronnstrand L. (1998) Signal transduction via platelet-derived growth factor receptors. Biochim. Biophys. Acta 1378, F79F113.
  • Hoch R. V. and Soriano P. (2003) Roles of PDGF in animal development. Development 130, 47694784.
  • Kotecha S. A., Oak J. N., Jackson M. F., Perez Y., Orser B. A., Van Tol H. H. and MacDonald J. F. (2002) A D2 class dopamine receptor transactivates a receptor tyrosine kinase to inhibit NMDA receptor transmission. Neuron 35, 11111122.
  • Lei S., Lu W. Y., Xiong Z. G., Orser B. A., Valenzuela C. F. and MacDonald J. F. (1999) Platelet-derived growth factor receptor-induced feed-forward inhibition of excitatory transmission between hippocampal pyramidal neurons. J. Biol. Chem. 274, 30 61730 623.
  • Oak J. N., Lavine N. and Van Tol H. H. (2001) Dopamine D(4) and D(2L) receptor stimulation of the mitogen-activated protein kinase pathway is dependent on trans-activation of the platelet-derived growth factor receptor. Mol. Pharmacol. 60, 92103.
  • Obadiah J., Avidor-Reiss T., Fishburn C. S., Carmon S., Bayewitch M., Vogel Z., Fuchs S. and Levavi-Sivan B. (1999) Adenylyl cyclase interaction with the D2 dopamine receptor family; differential coupling to Gi, Gz, and Gs. Cell. Mol. Neurobiol. 19, 653664.
  • O'Hara C. M., Uhland-Smith A., O'Malley K. L. and Todd R. D. (1996a) Inhibition of dopamine synthesis by dopamine D2 and D3 but not D4 receptors. J. Pharmacol. Exp. Ther. 277, 186192.
  • O'Hara C. M., Tang L., Taussig R., Todd R. D. and O'Malley K. L. (1996b) Dopamine D2L receptor couples to G α i2 and G α i3 but not G α i1, leading to the inhibition of adenylate cyclase in transfected cell lines. J. Pharmacol. Exp. Ther. 278, 354360.
  • Ronnstrand L., Mori S., Arridsson A. K., Eriksson A., Wernstedt C., Hellman U., Claesson-Welsh L. and Heldin C. H. (1992) Identification of two C-terminal autophosphorylation sites in the PDGFβ-receptor: involvement in the interaction with phospholipase C-γ. EMBO J. 11, 39113919.
  • Saito S., Frank G. D., Mifune M., Ohba M., Utsunomiya H., Motley E. D., Inagami T. and Eguchi S. (2002) Ligand-independent trans-activation of the platelet-derived growth factor receptor by reactive oxygen species requires protein kinase C-δ and c-Src. J. Biol. Chem. 277, 44 69544 700.
  • Sultzman L., Ellis C., Lin L. L., Pawson T. and Knopf J. (1991) Platelet-derived growth factor increases the in vivo activity of phospholipase C-γ1 and phospholipase C-γ2. Mol. Cell Biol. 11, 20182025.
  • Trantham-Davidson H., Neely L. C., Lavin A. and Seamans J. K. (2004) Mechanisms underlying differential D1 versus D2 dopamine receptor regulation of inhibition in prefrontal cortex. J. Neurosci. 24, 10 65210 659.
  • Tseng K. Y. and O'Donnell P. (2004) Dopamine–glutamate interactions controlling prefrontal cortical pyramidal cell excitability involve multiple signaling mechanisms. J. Neurosci. 24, 51315139.
  • Valenzuela C. F., Xiong Z., MacDonald J. F., Weiner J. L., Frazier C. J., Dunwiddie T. V., Kazlauskas A., Whiting P. J. and Harris R. A. (1996) Platelet-derived growth factor induces a long-term inhibition of N-methyl-d-aspartate receptor function. J. Biol. Chem. 271, 16 15116 159.
  • Valius M., Bazenet C. and Kazlauskas A. (1993) Tyrosines 1021 and 1009 are phosphorylation sites in the carboxy terminus of the platelet-derived growth factor receptor β subunit and are required for binding of phospholipase C γ and a 64-kilodalton protein, respectively. Mol. Cell. Biol. 13, 133143.
  • Wang L. Y. and MacDonald J. F. (1995) Modulation by magnesium of the affinity of NMDA receptors for glycine in murine hippocampal neurones. J. Physiol. 486, 8395.
  • Wang X., Zhong P., Gu Z. and Yan Z. (2003) Regulation of NMDA receptors by dopamine D4 signaling in prefrontal cortex. J. Neurosci. 23, 98529861.